Compare MLP & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MLP | VCRE |
|---|---|---|
| Founded | 1909 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.4M | 271.7M |
| IPO Year | 2010 | 2026 |
| Metric | MLP | VCRE |
|---|---|---|
| Price | $14.63 | $10.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $24.37 |
| AVG Volume (30 Days) | 14.1K | ★ 17.0K |
| Earning Date | 11-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,457,000.00 | N/A |
| Revenue This Year | N/A | $38.94 |
| Revenue Next Year | N/A | $694.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.24 | N/A |
| 52 Week Low | $13.76 | $7.88 |
| 52 Week High | $19.92 | $14.01 |
| Indicator | MLP | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 52.76 |
| Support Level | $14.03 | $8.83 |
| Resistance Level | $16.39 | $11.88 |
| Average True Range (ATR) | 0.56 | 0.42 |
| MACD | 0.09 | 0.11 |
| Stochastic Oscillator | 41.94 | 57.38 |
Maui Land & Pineapple Co Inc is a landholding and operating parent company that owns land and commercial property on the island of Maui, Hawaii. The Company puts its assets into productive use by planning, managing, developing, and selling residential, resort, commercial, agricultural, and industrial real estate. Its segments include land development and sales, which cover land planning, entitlement, development, construction, and sales of land assets; leasing, which generates revenue from real property leasing, license fees and royalties, and includes maintenance of real estate assets, conservation activities, and management of water systems in West and Upcountry Maui; and resort amenities, which include a membership program offering benefits within the Kapalua Resort.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.